Rani Therapeutics Holdings, Inc.
RANI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001856725
In the last 90 days, Rani Therapeutics Holdings, Inc. insiders filed 2 open-market purchases and 2 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Rani Therapeutics Holdings, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 34 | 34 | 0 |
| Shares | 3.21M | 3.29M | +81.7K (+2.5%) |
| Value | $6.96M | $10.9M | +$3.96M (+56.9%) |
New holders (2)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 338,679 | $1.12M | 0.34% |
| Tower Research Capital LLC (TRC) | 2,308 | $7.66K | 0.00% |
Sold out (2)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Millennium Management LLC | 46,137 | $100.3K |
| UBS Group AG | 5,700 | $12.4K |